This is the authors' abstract. We don't add key points for this paper.
In this exploratory post hoc analysis, pemafibrate was associated with sustained increases in platelet count and reductions in spleen volume in patients with MASLD, accompanied by a decline in liver stiffness. While platelet count changes likely reflect mechanisms independent of portal pressure, concordant changes in spleen volume and liver stiffness may represent a coherent noninvasive signal of improvement in portal hypertension-related hemodynamic stress. These hypothesis-generating findings warrant prospective validation using direct hemodynamic assessments and clinical outcomes in MASLD/MASH. ClinicalTrials.gov identifier: NCT03350165.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tanigawa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: